RDM1 plays an oncogenic role in clear cell renal cell carcinoma potentially by modulating MCM2

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Kidney cancer arises from various gene mutations, leading to distinct subtypes and prognoses.
• The role of RAD52 motif-containing 1 (RDM1) in clear cell renal cell carcinoma (ccRCC) remains largely unexplored.
• RDM1 is known to regulate multiple cancer-associated pathways.

Purpose of the Study:

• To investigate the role and mechanism of RDM1 in ccRCC.
• To determine the correlation between RDM1 expression and patient survival in ccRCC.
• To evaluate the therapeutic potential of RDM1 inhibition in ccRCC.

Main Methods:

• Quantitative analysis of RDM1 expression in ccRCC tissues and cell lines.
• In vitro and in vivo experiments involving RDM1 knockdown.
• Cell cycle analysis and apoptosis assays.
• Investigation of RDM1's interaction with MCM2.

Main Results:

• RDM1 expression was significantly increased in ccRCC cells compared to normal kidney tissues.
• Elevated RDM1 levels correlated with poorer overall survival in ccRCC patients.
• RDM1 knockdown resulted in cell cycle arrest, increased apoptosis, and suppressed tumor growth both in vitro and in vivo.
• RDM1 was found to modulate the ccRCC cell cycle by interacting with MCM2.

Conclusions:

• RDM1 is upregulated in ccRCC and serves as a prognostic biomarker for poor survival.
• RDM1 inhibition effectively suppresses ccRCC cell proliferation and induces apoptosis.
• Targeting RDM1, potentially through its interaction with MCM2, represents a promising therapeutic strategy for ccRCC treatment.